

8 4 9 5 ' 0 1 JUN 26 A 9 : 3 5

June 25, 2001

Dockets Management Branch
HFA-305
Food and Drug Administration
5630 Fishers Lane
Room 1061
Rockville, MD 20852

Dear Messrs/Madams:

Cubist Pharmaceuticals has reviewed "Reference Docket No. 00N-1269 (Requirements on Content and Format of Labeling for Human Prescription Drugs and Biologics: Requirements for Prescription Drug Product Labels)". This proposal to remove information related to the potency of an anti-infective from the package insert represents a dramatic change. The suppression of validated medical information is unlikely to improve prescription practice or decrease the incidence of bacterial resistance. The likely result of this proposal is an increase in appropriate usage of antibiotics as physicians are forced to choose therapies without specific potency information. Cubist Pharmaceuticals strongly believes that *in vitro* MIC data should be retained in antibiotic package inserts. The following specific comments are offered:

The current wording in drug package insert (i.e., "The following *in vitro* data are available, but their clinical significance is unknown... However, the safety and efficacy of [drug] have not been established in adequate and well-controlled clinical trials.") clearly communicates the limitations of the data. Bacterial MIC values are included in the *in vitro* section of an anti-infective's package insert (PI) only if (1) they are associated with an infection that appears in the "approved indications" section of the PI; and (2) at least 90% of the strains tested were susceptible *in vitro*, using the approved interpretive breakpoints. These breakpoints are developed and approved based on susceptibility population studies, pharmacokinetic and pharmacodynamic studies, and drug resistance studies. These data should be included in the package insert.

Cubist Pharmaceuticals supports the proposal wording of the change proposed by Dr. F. Marsik and H. Silver in their January 19, 2001 comments to the docket. The new wording appears to be even more useful in educating physicians about how to interpret the "*in vitro*" section:

00N-1269

C59

"The pharmacological parameters and *in vitro* susceptibility data for the drug suggest *in vivo* activity against the following organisms for infection occurring at those sites indicated under "Indications and Usage". This has not been proven clinically."


Many antimicrobial therapies must be initiated with incomplete knowledge of the pathogen(s). The precise species is almost never known when empiric therapy is started. Knowledge of the spectrum of activity for an antibiotic is essential to both the selection of the most appropriate drug and the adjustment of therapy in the case of apparent failure.

Removal of the *in vitro* section of an anti-infective package insert will effectively remove a large amount of information needed by physicians to determine proper course of action at initiation and during therapy.

Many pathogens do not occur frequently enough in clinical trials to be included in the "indicated uses" section. However, these pathogens are often both susceptible to antibiotics and cause infections in body sites for which the antibiotics are approved. Excluding these organisms from the "*in vitro*" section of drug package insert will make it more difficult to physicians to know proper treatments for infections caused by those particular species.

In summary, Cubist Pharmaceuticals believes that bacterial susceptibility data should be included in the package insert for all pathogens in which 90% of the isolates are susceptible under approved breakpoints. This will require no change and will allow for valuable information to continue to be disseminated to physicians. While Cubist Pharmaceuticals desires to combat the spread of drug resistance, the exclusion of potency information from the package insert is unlikely to decrease the standard of medical care without producing a reduction in incidence of drug resistance.


Sincerely,




Francis P. Tally, M.D.
Executive Vice President
Scientific Affairs




Robert McCormack, Ph.D.
Senior Vice President
Drug Development



Michael DeBruin, M.D.
Vice President
Clinical Research



Jeffrey Alder, Ph.D.
Senior Director
Microbiology and Pharmacology



Grace M. Thorne, Ph.D.
Director, Clinical
Microbiology

199
400

FedEx USA Airbill
Express

FedEx
Tracking
Number

827328107603

Form
I.D. No.

0215

Recipient's Copy

RECIPIENT: PEEL HERE

1 From This portion can be removed for Recipient's records.

Date 06/25/01 FedEx Tracking Number 827328107603

Sender's Name Grace Thorne Phone 617 576-1999

Company CUBIST PHARMACEUTICALS INC

Address 24 EMILY ST

City CAMBRIDGE State MA ZIP 02139

2 You Internal Billing Reference

3 To Recipient's Name Dockets Management Branch
HFA-305 Phone

Company Food and Drug Administration

Address 5630 Fisher Lane
To "HOLD" at FedEx location, print FedEx address. We cannot deliver to P.O. boxes or F.D. ZIP codes.

Room 1061

City Rockville State MD ZIP 20852



4a Express Package Service

FedEx Priority Overnight Next business morning FedEx Standard Overnight Next business afternoon FedEx First Overnight Earliest next business morning delivery to select locations
 FedEx 2Day* Second business day FedEx Express Saver* Third business day
* FedEx Envelope/Letter Rate not available. Minimum charge: One-pound rate.

4b Express Freight Service

FedEx 1Day Freight* Next business day FedEx 2Day Freight Second business day FedEx 3Day Freight Third business day
* Call for confirmation. Packages over 150 lbs. Delivery commitment may be later in some areas.

5 Packaging

FedEx Envelope/Letter* FedEx Pak* Other Pkg. Includes FedEx Box, FedEx Tube, and customer pkg.
* Declared value limit \$500

6 Special Handling

SATURDAY Delivery Available only for FedEx Priority Overnight and FedEx 2Day to select ZIP codes SUNDAY Delivery Available only for FedEx Priority Overnight to select ZIP codes HOLD Weekday at FedEx Location Not available with FedEx First Overnight HOLD Saturday at FedEx Location Available only for FedEx Priority Overnight and FedEx 2Day to select locations
Include FedEx address in Section 3.

Does this shipment contain dangerous goods?
 NO YES As per attached Shipper's Declaration YES Shipper's Declaration not required Dry Ice Dry Ice, 9, UN 1845 x _____ kg
Dangerous Goods cannot be shipped in FedEx packaging. Cargo Aircraft Only

7 Payment Bill to:

Sender Acct. No. in Section 1 will be billed. Recipient Third Party Credit Card Cash/Check Obtain Recip. Acct. No.

Total Packages: 1 Total Weight: _____ Total Charges: _____
Credit Card Auth. _____
*Our liability is limited to \$100 unless you declare a higher value. See the FedEx Service Guide for details.

8 Release Signature Sign to authorize delivery without obtaining signature.

By signing you authorize us to deliver this shipment without obtaining a signature and agree to indemnify and hold us harmless from any resulting claims.
Questions? Visit our Web site at www.fedex.com
or call 1-800-Go-FedEx (800)463-3339.
Rev. Date 7/00 Part #1553125 ©1994-2000 FedEx PRINTED IN U.S.A. GBFE 2/01

402

0173958519